학술논문
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
Document Type
Article
Author
Source
In The Lancet Rheumatology June 2022 4(6):e407-e416
Subject
Language
ISSN
2665-9913